• Possis Medical (Minneapolis) reported the introduction of the SafeSeal Hemostasis Patch, a topical wound dressing that decreases the time it takes to control bleeding from the puncture made into a blood vessel to perform an endovascular procedure. Designed to assist manual pressure and complement invasive vessel closure techniques, the SafeSeal Patch employs a micro-bead material that has been used extensively to control bleeding in humans in a variety of settings such as trauma and post-operative surgical wounds. Called Microporous Polysaccharide Hemospheres (MPH), and developed by Medafor (Minneapolis), MPH technology works by dehydrating the blood at the wound site causing faster and stronger clotting. The design of the SafeSeal Patch features a clear window that aids in positioning the patch and viewing the condition of the wound.

• Stem Cell Therapeutics (Calgary, Alberta) said that the U.S. Patent and Trademark Office has granted U.S. patent No. 7,033,995 to the company's wholly owned subsidiary, Stem Cell Therapeutics. The patent, “Production of Radial Glial Cells,” protects methods of producing radial glial cells in the brain. The production of radial glial cells in the brain of a patient suffering from a central nervous system (CNS) disease has the potential to be a fundamental technology in the field, key to the successful development of neural stem cell based approaches for the treatment of many CNS diseases, the company said. The patent describes methods to cause neural stem cells present in the adult brain to make radial glia. The new radial glial cells act like those found in the developing fetal brain and direct the migration of newly generated neurons out into the deep tissues of the brain.

• Synergetics USA (O'Fallon, Missouri), a manufacturer of vitreoretinal (ophthalmology) surgical instruments, said that it has manufactured and released the first four models in its soon-to-be comprehensive line of Malis Bipolar forceps and accessories. The company said the Malis Bipolar forceps represents a new product line extension for Synergetics and a strategic introduction into the growing $43 million bipolar forceps market.

• Systat Software (Point Richmond, California), a developer of scientific software and services, reported the launch of SigmaPlot 10, the latest version of its scientific graphing and data analysis software package. SigmaPlot 10 provides researchers new features to confidently analyze data and create exact, publication-quality graphs that best present research results for presentation, publication or the web. The latest version contains many workflow efficiency improvements, new enhancements to SigmaPlot's curve fitting engine, and a wider range of graphing options that allow users to easily customize every detail of their graphs for effectively communicating the most important elements of their research. By integrating SigmaPlot 10 with SigmaStat 3.5, the step-by-step guided statistical analysis software package for scientists who are not statisticians, users can access 30 of the most frequently used statistical procedures for analyzing scientific research directly from the SigmaPlot statistics menu.

• Triage Medical (Irvine, California) reported completion of enrollment in a 10-patient study of its Percutaneous Dynamic Stabilization (PDS) system. Juan Dipp, MD, the clinical investigator for this pilot study, reported excellent acute results in all 10 patients with follow-up data ranging from two weeks to three months post-procedure. Complete results of this initial study will be available late in 2006. “The PDS system one-size-fits-all device implanted using the Teleport over-the-guide-wire access technology provided a quick and easy procedure, with reduced patient recovery time and an excellent acute patient outcome,” Dipp said. The company said its PDS system is the least invasive, extension limiting dynamic stabilization device currently under development.